ID.1
Item
patients who are on antiangiogenic therapy for a minimum of 4 weeks and have isolated metastatic lesions showing either persistence or resistance to therapy that might benefit from local therapy such as rf ablation.
boolean
C2363719 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
ID.2
Item
male or female patients 18 years of age or older
boolean
C0001779 (UMLS CUI [1])
ID.3
Item
clinical, radiographic, or pathologic diagnosis of clear cell rcc
boolean
C0279702 (UMLS CUI [1])
ID.4
Item
ongoing treatment with sorafenib or sunitinib, off clinical trials
boolean
C1516119 (UMLS CUI [1,1])
C1176020 (UMLS CUI [1,2])
ID.5
Item
acceptable risk for general anesthesia in the judgement of the study investigator and by the department of anesthesiology upon preoperative testing.
boolean
C0035649 (UMLS CUI [1,1])
C0002915 (UMLS CUI [1,2])
ID.6
Item
at least one lesion that has not completely resolved while on antiangiogenic therapy
boolean
C0221198 (UMLS CUI [1,1])
C2699488 (UMLS CUI [1,2])
ID.7
Item
candidate lesions of 1cm or greater in diameter
boolean
C0221198 (UMLS CUI [1,1])
C0456389 (UMLS CUI [1,2])
ID.8
Item
safe access to the tumor for a needle placed under ultrasound guidance
boolean
C2041187 (UMLS CUI [1])
ID.9
Item
ecog performance status of 0 or 1
boolean
C1520224 (UMLS CUI [1])
ID.10
Item
adequate bone marrow, and renal as assessed by the laboratory requirements outlined in the protocol
boolean
C0005953 (UMLS CUI [1,1])
C0232804 (UMLS CUI [1,2])
ID.11
Item
history of bleeding diathesis or unexpected surgical bleeding
boolean
C0005779 (UMLS CUI [1])
ID.12
Item
patients currently on anticoagulation
boolean
C0003281 (UMLS CUI [1])
ID.13
Item
medical contraindication to mr imaging (pacemaker, metal debris in eye, etc.)
boolean
C0522473 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
ID.14
Item
prior rf to the index tumor
boolean
ID.15
Item
pregnant or lactating
boolean
C0600457 (UMLS CUI [1,1])
C2828358 (UMLS CUI [1,2])